Have any questions? 706-721-6582 or cts@augusta.edu
- (PERFUSE) AEGIS-II: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
Clinical Trial
(PERFUSE) AEGIS-II: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
This study is to find out how effective and safe a new drug, CSL112, is. It is for people who recently have had heart attack. We hope this new drug will help prevent another heart attack or a stroke. We also hope that it will reduce the risk of dying from heart related events.
Eligibility Criteria
- a) Male or female at least 18 years of age at time of giving informed consent b) clinical evidence of having had heart attack (MI) c) Clinical evidence of multivessel coronary artery disease d) not pregnant e) hemodynamically stable f) not allergic to soy or peanuts g) no liver or kidney disease
RESEARCH. INNOVATION. DISCOVERY.